

Erin Ferries, PhD, MPH¹*, Susan Suponcic, BA, MA, MSc, PhD², Sophia Chung, BA³, Sayak Bhattacharya, BA³, Aishwarya Kulkarni, MS³, Mason Yeh, PhD³, Abigail Silber, MPH³, Matt O'Hara, MBA³, Phong Duong, PharmD⁴ 1. Mindmed, HEOR, Denver, CO; 2. Value and Access Advisors, LLC, St. Petersburg, FL; 3. Trinity Life Sciences, Waltham, MA; 4. Mindmed, New York, NY

INTRODUCTION & OBJECTIVES

- GAD is defined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), as a condition characterized by excessive anxiety and worry occurring for at least six months, causing significant distress or impairment¹
- Despite the extensive literature published on GAD, there exists an unmet need to address the burden of illness with the current disease management practices; patients with GAD often report diminished quality of life characterized by persistent anxiety, difficulty in daily functioning, increased healthcare utilization and cost of care, including more frequent visits to healthcare providers and therapy sessions^{2,3}
- Data presented reflects an interim analysis (literature published between 2019-2024) of a comprehensive literature review, which captures 20 years of literature (2004-2024) in GAD to assess and characterize GAD symptoms, clinical manifestations, comorbidities, and evaluate the impact of GAD on the activities of daily living (ADLs) and quality of life (QoL)


METHODS

- The SLR was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist
- Systematic searches in PubMed and Embase were performed using predefined search terminologies focusing on epidemiology, clinical outcomes, economic outcomes, or humanistic outcomes in GAD **(Table 1)**
- Manuscripts and conference abstracts, published from November 1st, 2019, to November 11th, 2024, meeting the eligibility criteria were included
- Identified articles were uploaded to an artificial intelligence (AI)enhanced platform used to facilitate the SLR process; duplicates across the databases were removed in the platform (Figure 1)
- Title/abstract screening was conducted per the defined population, intervention, comparator, outcomes, and study design (PICOS) criteria by one human researcher in parallel with one AI screener providing reviewer-level decisions; adjudication was performed by an independent human researcher
- In line with the ISPOR guidelines on the AI use for SLRs, the validated AI screening platform was initially trained using 50 adjudicated screening decisions and 10 inclusions before activation, and continued to improve its performance through subsequent screening
- After screening, full texts were retrieved and screened by two independent human reviewers, facilitated via the AI platform; data from included studies were extracted in a Microsoft Excel[™] grid

| CATEGORY | OVERVIEW OF KEY SEARCH TERMS | | |
|-----------------------|---|--|--|
| Epidemiology | Prevalence OR Incidence OR Guideline OR Diagnosis OR Disease management OR Treatment pattern | | |
| Clinical Outcome | Symptom OR Severity OR Prognosis OR Generalized anxiety disorder scale OR Treatment preference OR Safety OR Dose-response | | |
| Economic Outcome | Cost of illness OR Health expenditure OR Cost effectiveness OR Healthcare resource OR Productivity OR Indirect cost OR Caregiver cost | | |
| Humanistic Outcome | Patient reported outcome OR Quality of life OR Patient satisfaction OR QALY OR DALY OR Activities of Daily living OR Patient assessment | | |

Table 1 Overview of Key Search Terms


Ask A Question:



Study Topics Figure 2

| Topic Name | Frequency of Studies | |
|------------------------------------|----------------------|--|
| GAD Primary/Secondary Epidemiology | 123 | |
| GAD Comorbidities | 105 | |
| Humanistic Burden of GAD | 62 | |
| GAD Clinical manifestations | 52 | |
| GAD DSM V Symptoms | 43 | |

*The sum of the studies is higher than 156, as one study may provide data on more than one topic **Figure 3** | Frequency of Conditions Co-occurring with GAD



- Comorbid GAD in patients with pancreatitis, morbid obesity, and those with OCD are associated with worsened outcomes, including increased risk of mortality, increased risk of treatment failure, increased suicide risk, and higher admission rates⁴⁻⁷
- In patients with respiratory disease, bacterial infections, and HIV, GAD was associated with increased likelihood of experiencing delirium in ICU patients, alters gut microbiota, lowers the remission rate, and increases risk of new-onset cardiovascular disease⁸⁻¹⁰

Please scan the QR code for the full list of references and abbreviations

Table 2. List of Conditions Captured as GAD Comorbidities

| Mental Disorders | Gastroenterology ^{49,50} | Other | Immunology |
|------------------------------------|--|--------------------------------------|-----------------------------------|
| Bipolar Disorder ¹¹ | Chronic pancreatitis ⁴ | Cancer ⁵⁹⁻⁶¹ | Allergy ⁷¹ |
| BPD ¹² | C. Difficile Infection ⁹ | Pregnancy ⁶²⁻⁶⁵ | Dermatomyositis ⁷² |
| Depression ¹³⁻¹⁵ | Diverticulosis ⁵¹ | Trauma ⁶⁶ | HIV ⁷³⁻⁷⁶ |
| Eating Disorder ¹⁶⁻¹⁸ | Gastrointestinal bleed ⁵² | Surgery ^{6,67,68} | Celiac Disease+77 |
| Hoarding Disorder ^{19,20} | Mallory Weiss Syndrome ⁵³ | Chronic Diseases ^{37,69.70} | Neurology |
| MDD ²¹⁻³⁷ | Gastroparesis ⁵⁴ | | |
| OCD ^{5,38,39} | GERD ⁵⁵ | Cardiovascular ⁸⁹ रि | Alzheimer's Disease ⁸³ |
| PTSD ⁴⁰ | IBD* 56,57 | | Mal de Debarquement |
| SAD ⁴¹ | IBS ⁵⁸ | Coronary Artery Disease ⁸ | Syndrome ⁸⁴ |
| Substance use ^{42-46,74} | | Peripartum | Migraine ⁸⁵ |
| Suicidal ideation ⁴⁷ | Dermatology | Cardiomyopathy ⁹⁰ | Respiratory |
| Trichotillomania ⁴⁸ | | Aneurysm ⁹¹ | |
| | Alopecia ⁷⁸ | | Asthma ⁸⁶ |
| | Skin-picking disorder ⁷⁹⁻⁸¹ | | Acute Respiratory Distres |
| | Vitiligo ⁸² | | Syndrome ^{87,88} |

*IBD is an autoimmune disease and can be grouped with immunology disorders; +Celiac disease can have dermatological and gastrointestinal manifestations Note: The most common GAD comorbidities are **bolded** in Table 2

treating GAD in these patients (Figure 3 and Table 2) life, additional psychiatric disorders, social adjustment problems, etc.^{25,27} outcomes are a direct result of either indication

GAD Symptoms

- and depression^{14,38,92,105}

- **Sleep Disturbances:** Patients with GAD often report insomnia symptoms and poor sleep quality⁹⁵⁻¹⁰¹

GAD Clinical Manifestation

- visuospatial functions⁹²
- compared to healthy patients¹⁰²

Impact on Quality of Life (QoL) and Activities of Daily Living (ADLs)

Healthcare Resource Utilization (HCRU)

DISCUSSION AND CONCLUSIONS

- published in the US within the last 5 years (2019-2024)
- disease-state awareness or improved patient outcomes
- treatment paradigms, existing burden despite treatments, etc.)

Connect With Us:



QR Code



• Numerous conditions occur as GAD comorbidities and vice versa, highlighting the complexity of diagnosing and

GAD and major depressive disorder (MDD) are highly comorbid, with an estimated 62% of GAD patients reporting a MDD episode in their lifetime⁶⁹; this relationship is mediated by factors including poor sleep quality, poor quality of

Current literature often reports outcomes for a heterogeneous population of patients with GAD or MDD, though it is unclear which

Elevated Anxiety and Depression: Patients with GAD show significantly higher levels of anxiety, stress,

Neuroticism: Young adults with high neuroticism have a 33.93% incidence of GAD, compared to 17% for MDD⁹³ **Self-injury:** GAD is associated with the subsequent onset and higher severity of non-suicidal self-injury⁹⁴

Cognitive and Motor Deficits: GAD patients underperform in information processing, motor skills, verbal, and

Psychophysiological Parameters: Upon stress removal, patients with GAD had reduced heart rate recovery

Health-Related Quality of Life: When compared to healthy controls, GAD patients reported significantly reduced QoL; greater impairment in patients with more severe anxiety symptoms or additional comorbidities^{69,103}

Increased and Inconsistent Resource Use: The co-occurrence of GAD with other disease conditions significantly increases the likelihood of missed routine appointments, higher number of emergency or urgent care visits, prolonged hospital stays, greater incidence of complications, and reduced adherence to medications^{44,51-54,56,104}

This SLR serves as an interim of a comprehensive analysis of GAD literature published over the past 20 years; results presented herein specifically capture data from observational studies/non-RCT/clinical trial reports

• The high degree of comorbidity among patients with GAD complicates the diagnosis and treatment of GAD

Literature in GAD is extensive, but little progress has been made to translate this knowledge base into increased

A comprehensive review of articles published over the past 20 years will generate a foundational resource to inform key gaps in our understanding and perception of GAD (e.g., patient journey, impact on QOL, current



Erin Ferries, PhD, MPH¹*, Susan Suponcic, BA, MA, MSc, PhD², Sophia Chung, BA³, Sayak Bhattacharya, BA³, Aishwarya Kulkarni, MS³, Mason Yeh, PhD³, Abigail Silber, MPH³, Matt O'Hara, MBA³, Phong Duong, PharmD⁴ 1. Mindmed, HEOR, Denver, CO; 2. Value and Access Advisors, LLC, St. Petersburg, FL; 3. Trinity Life Sciences, Waltham, MA; 4. Mindmed, New York, NY

REFERENCES

1. Munir S, Takov V. Generalized Anxiety Disorder. [Updated 2022 Oct 17]. In: StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK441870/ 2. Hoffman DL, Dukes EM, Wittchen HU. Human and economic burden of generalized anxiety disorder. Depress Anxiety. 2008;25(1):72-90. https://doi.org/10.1002/da.20257 3. Yang, X., Fang, Y., Chen, H., Zhang, T., Yin, X., Man, J., Yang, L., & Lu, M. (2021). Global Burden of Disease Study 2019. Epidemiology and psychiatric sciences, 30, e36. https://doi.org/10.1017/S2045796021000275 4. Aminmozaffari S, Dolan R, Lee A, et al. THE IMPACT OF PSYCHIATRIC DISORDERS ON HEALTHCARE UTILIZATION IN PATIENTS WITH CHRONIC PANCREATITIS. Gastroenterology. 2021;160(6):S-301. doi:10.1016/s0016-5085(21)01442-6. 5. Benatti B, Dell'Osso B, Shen H, et al. Prevalence and correlates of current suicide risk in an international College of Obsessive-Compulsive Spectrum Disorders (ICOCS) network and Obsessive Compulsive and Related Disorders Network (OCRN) of the European College of Neuropsychopharmacology. J Psychiatr Res. 2021;140:357-363. doi:10.1016/j.jpsychires.2021.05.054. 6. Katakam A, Melnic C, Bedair H. Morbid Obesity Is a Risk Factor for Infection Recurrence Following Debridement, Antibiotics, and Implant Retention for Periprosthetic Joint Infection. J Arthroplasty. 2020;35(12):3710-3715. doi:10.1016/j.arth.2020.07.005. 7. Brooks J, Umucu E, Fortuna K, Reid M, Tracy K, Poghosyan L. Prevalence of lifetime nonmedical opioid use among U.S. Health Center Patients aged 45 years and older with psychiatric disorders. Aging Ment Health. 2022;26(1):179-185. doi:10.1080/13607863.2020.1855105. 8. Liu H, Tian Y, Liu Y, Nigatu Y, Wang J. Relationship between major depressive disorder, general population. J Psychosom Res. 2019;119:8-13. doi:10.1016/j.jpsychores.2019.01.007. 9. Patel S, Kaye A, Meyers S, Saiganesh P, Ahlawat S. Outcomes of Clostridioides difficile Infection in Hospitalized Anxiety Disorder. Am. J. Gastroenterol. 2022;117(10):S172. doi:10.14309/01.ajg.0000857616.64288.ca. 10.Lavakumar M, Lewis S, Webel A, et al. Correlates of depression outcomes in collaborative care for HIV. Gen Hosp Psychiatry. 2020;66:103-111. doi:10.1016/j.genhosppsych.2020.05.002. 11.Sanchez Ruiz J, Coombes B, Pendegraft R, et al. Pharmacotherapy exposure as a marker of disease complexity in bipolar disorder: Associations with clinical & genetic risk factors. Psychiatry Res. 2023;323:115174. doi:10.1016/j.psychres.2023.115174. 12.Ward M, Benjamin I, Zimmerman M. The Clinical Characteristics of Patients With Borderline Personality Disorder in Different Treatment Settings. J Pers Disord. 2022;36(2):217-229. doi:10.1521/pedi_2021_35_536. 13.0'Toole M, Renna M, Mennin D, Fresco D. Changes in Decentering and Reappraisal Temporally Precede Symptom Reduction Therapy for Generalized Anxiety Disorder With and Without Co-Occurring Depression. Behav Ther. 2019;50(6):1042-1052. doi:10.1016/j.beth.2018.12.005. 14.Ziobrowski H, Leung L, Bossarte R, et al. Comorbid mental disorders, depression treatment through the Veterans Health Administration. J Affect Disord. 2021;290:227-236. doi:10.1016/j.jad.2021.04.033. 15.Brendle M, Ahuja S, Valle M, et al. Safety and effectiveness of intranasal esketamine for treatment-resistant depression: a real-world retrospective study. J Comp Eff Res. 2022;11(18):1323-1336. doi:10.2217/cer-2022-0149. 16.Garcia S, Mikhail M, Keel P, et al. Increased rates of eating disorders and their symptoms in women with major depressive disorders. Int J Eat Disord. 2020;53(11):1844-1854. doi:10.1002/eat.23366. 17.D'Adamo L, Grammer A, Rackoff G, et al. Preferred treatment focus among college students with eating disorders and comorbid mental health problems in a digital cognitive-behavioral guided self-help program. Int J Eat Disord. 2023;56(12):2349-2357. doi:10.1002/eat.24065. 18.Thompson C, Martin-Wagar C. Cognitive flexibility and emotion regulation in eating disorder patients with comorbid generalized anxiety and posttraumatic stress symptoms. Eating Disord. 2024;doi:10.1080/10640266.2024.2405290. 19.Siev J, Darst-Campbell M, Rouder I, Schlaudt V. Grit predicts less severe hoarding symptoms among patients seeking treatment at an anxiety disorders clinic. Bull Menninger Clin. 2022;86(1):20-34. doi:10.1521/bumc.2022.86.1.20. 20.Sordo Vieira L, Guastello A, Nguyen B, et al. Identifying psychiatric and neurological comorbidities associated with hoarding disorder through network analysis. J Psychiatr Res. 2022;156:16-24. doi:10.1016/j.jpsychires.2022.09.037. 21.Mellick W, Mills J, Kroska E, Calarge C, Sharp C, Dindo L. Experiential Avoidance Predicts Persistence of Major Depressive Disorder in Late Adolescence. J Clin Psychiatry. 2019;80(6). doi:10.4088/jcp.18m12265. 22.Aderka I, Kauffmann A, Shalom J, Beard C, BjĶrgvinsson T. Using machine-learning to predict sudden gains in treatment for major depressive disorder. Behav Res Ther. 2021;144:103929. doi:10.1016/j.brat.2021.103929. 23.Rep C, Peyre H, SÄinchez-Rico M, et al. Contributing factors to heterogeneity in the timing of the onset of major depressive episode: Results from a national study. J Affect Disord. 2022;299:585-595. doi:10.1016/j.jad.2021.12.082. 24.Liu K, Droncheff B, Warren S. Predictive utility of symptom measures in classifying anxiety and depression: A machine-learning approach. Psychiatry Res. 2022;312:114534. doi:10.1016/j.psychres.2022.114534. 25.Nguyen V, Zainal N, Newman M. Why Sleep is Key: Poor Sleep Quality is a Mechanism for the Bidirectional Relationship between Major Depressive Disorder Across 18 Years. J Anxiety Disord. 2022;90:102601. doi:10.1016/j.janxdis.2022.102601. 26.Barber K, Zainal N, Newman M. The mediating effect of stress reactivity in the 18-year bidirectional relationship between generalized anxiety and depression severity. J Affect Disord. 2023;325:502-512. doi:10.1016/j.jad.2023.01.041. 27.Jegede O, Stefanovics E, Rhee T, Rosenheck R. Multimorbidity and Correlates of Comorbid Depression and Generalized Anxiety Disorder in a Nationally Representative US Sample. J Nerv Ment Dis. 2023;211(5):355-361. doi:10.1097/nmd.00000000000001625. 28.Terrill D, Dellavella C, King B, Hubert T, Wild H, Zimmerman M. Latent classes of symptom trajectories during partial hospitalization for major depressive disorder. J Affect Disord. 2023;331:101-111. doi:10.1016/j.jad.2023.03.036. 29.Milgram L, Timpano K. A Network Analysis of GAD, MDD, and OCD: Symptom Overlap and Shared Risk/Maintenance Factors. J. Psychopathol. Behav. Assess. 2024;46(3):821-838. doi:10.1007/s10862-024-10156-x. 30.Geller J, Keith K, Smith C, et al. Response to Ketamine treatment for major depressive disorder not associated with number of psychiatric comorbidities. J. Affec. Disord. Rep. 2024;15. doi:10.1016/j.jadr.2023.100688. 31.Shin J, Fischer I, Na P, Jeste D, Pietrzak R. Successful Aging in US Veterans with Mental Disorders: Results From the National Health and Resilience in Veterans Study. Am. J. Geriatr. Psychiatry. 2024; doi:10.1016/j.jagp.2024.07.018. 32.Hu Y, Nassan M, Singh B, Croarkin P, Kung S. Response rate underreports improvement in patients with major depressive disorder and comorbidities treated with repetitive transcranial magnetic stimulation (rTMS). Psychiatry Res. Commun. 2022;2(2). doi:10.1016/j.psycom.2022.100033. 33.Marr N, Zainal N, Newman M. Focus on and venting of negative emotion mediates the 18-year bi-directional relations between major depressive disorder and generalized anxiety disorder diagnoses. J. Affective Disord. 2022;303:10-17. doi:10.1016/j.jad.2022.01.079. 34.Narwal K. "THE OUTCOMES & COMPARATIVE EFFICACY OF LEFT VS RIGHT SIDED TMS FOR FEMALES WITH A CO-DIAGNOSIS OF MDD & GAD†Brain Stimul. 2021;14(5):1410-1411. doi:10.1016/j.brs.2021.07.042. 35.Morris T, Engelbertson A, Guidice W. Repetitive Transcranial Magnetic Stimulation (rTMS): A Large-Scale Retrospective Transcranial Magnetic Stimulation (rTMS): A Large-Scale Retrospective Transcranial Magnetic Stimulation (rTMS): A Large-Scale Retrospective Clinical Data Analysis Indicating rTMS as Effective Treatment for Generalized Anxiety Disorder (GAD). Brain Stimul. 2020;13(6):1843. doi:10.1016/j.brs.2020.06.021. 36.Nassan M, Hu Y, Kung S, Croarkin P. Psychiatric comorbidities did not influence remission and response rates in patients treated with transcranial magnetic stimulation (TMS) for major depressive disorder. Brain Stimul. 2020;13(6):1851-1852. doi:10.1016/j.brs.2020.06.047. 37.Armbrecht E, McIntyre R, Shah R, et al. PMH63 HUMANISTIC BURDEN ASSOCIATED WITH MAJOR DEPRESSIVE DISORDER AMONG ADULTS WITH NON-COMMUNICABLE DISEASES (NCCDS) IN THE UNITED STATES. Value Health. 2020;23:S211. doi:10.1016/j.jval.2020.04.677. 38. Gillan C, Kalanthroff E, Evans M, et al. Comparison of the Association Between Goal-Directed Planning and Self-reported Compulsivity vs Obsessive-Compulsive Disorder Diagnosis. JAMA Psychiatry. 2020; 77(1): 77-85. doi: 10.1001/jamapsychiatry. 2019. 2998. 39.Snorrason I, Beard C, Peckham A, BjĶrgvinsson T. Transdiagnostic dimensions in obsessive-compulsive and related disorders: associations with internalizing symptoms. Psychol Med. 2021;51(10):1657-1665. doi:10.1017/s0033291720000380. 40.Marshall V, Hooper S, Gomez F, Middlemass K, Kilpela L, Becker C. Posttraumatic stress disorder and other mental health correlates in a predominantly Latino/Hispanic sample living with food insecurity. Psychol Trauma. 2023;15(7):1094-1101. doi:10.1037/tra0001503. 41.Goetter E, Frumkin M, Palitz S, et al. Barriers to mental health treatment among individuals with social anxiety disorder and generalized anxiety disorder. Psychol Serv. 2020;17(1):5-12. doi:10.1037/ser0000254. 42.Subica A, Guerrero E, Martin T, et al. Native Hawaiian/Pacific Islander alcohol, tobacco and other drug use, mental health and treatment need in the United States during COVID-19. Drug Alcohol Rev. 2022;41(7):1653-1663. doi:10.1111/dar.13522. 43.ALCOHOL DEPENDENCE - GENERALIZED ANXIETY DISORDER, SOCIAL ANXIETY DISORDER AND DEPRESSION. Indian J. Psychiatry. 2024;66:S113. 44.Kaye A, Razdan R, Meyers S, Ahlawat S. Outcomes of Patients Hospitalized for Acute Alcoholic Hepatitis With Comorbid Generalized Anxiety Disorder. Am. J. Gastroenterol. 2022;117(10):S957-S958. doi:10.14309/01.ajg.0000861960.50330.ad. 45.Mondi C, Giovanelli A, Ou S, Reynolds A. Psychiatric and substance use disorders in a predominately low-income, black sample in early midlife. J. Psychiatr. Res. 2022;148:332-339. doi:10.1016/j.jpsychires.2022.02.008. 46.Bodofsky E, Sabia M, Heil J. Risk of Addiction, Depression, Anxiety and Childhood Abuse in Chronic Pain Patients. PM R. 2022;14:S17-S18. doi:10.1002/pmrj.12913. 47.Middleton V, Monira N, Kriske J, Wiebold T, Donachie N, Downar J. Effectiveness of unilateral vs. bilateral rTMS treatment on suicidal ideation in patients with depression and comorbid anxiety. Brain Stimul. 2021;14(6):1632-1633. doi:10.1016/j.brs.2021.10.144. 48.Grant J, Collins M, Chamberlain S. Clinical characteristics of trichotillomania. Ann Clin Psychiatry. 2023;35(4):228-233. doi:10.12788/acp.0120. 49.Renna M, O'Toole M, Fresco D, Heimberg R, Mennin D. From psychological to physical health: Exploring temporal precedence throughout emotion regulation therapy. J Anxiety Disord. 2021;80:102403. doi:10.1016/j.janxdis.2021.102403. 50.Dendrinos E, Hubik D, Wong O, et al. Psychiatry integration in a multidisciplinary functional gastrointestinal disorder clinic. J. Gastroenterol. Hepatol. Res. 2022;37:199-200. doi:10.1111/jgh.15955. 51.Kaye A, Patel S, Meyers S, Saiganesh P, Ahlawat S. Outcomes of Patients Hospitalized for Acute Diverticulitis With Comorbid Generalized Anxiety Disorder. Am. J. Gastroenterol. 2022;117(10):S170. doi:10.14309/01.ajg.0000857604.20660.51. 52.Kaye A, Meyers S, Baker B, Shaikh A, Meybodi M, Ahlawat S. OUTCOMES OF UPPER GASTROINTESTINAL BLEED IN PATIENTS WITH GENERALIZED ANXIETY DISORDER. Gastroenterology. 2022;162(7):S-1042. doi:10.1016/s0016-5085(22)62480-6. 53.Kaye A, Meyers S, Tangella N, Meybodi M, Ahlawat S. OUTCOMES OF MALLORY-WEISS SYNDROME IN PATIENTS WITH GENERALIZED ANXIETY DISORDER. Gastroenterology. 2022;162(7):S-1042. doi:10.1016/s0016-5085(22)62481-8. 54.Patel S, Kaye A, Meyers S, Mathew A, Ahlawat S. Outcomes of Hospitalized Anxiety Disorder. Am. J. Gastroenterol. 2022;117(10):S1156. doi:10.14309/01.ajg.0000863104.05880.74. 55. Davila J, El Hage Chehade N, Saleh S, et al. Major depressive disorder and its complications: A nationwide study. Am. J. Gastroenterol. 2021;116 (SUPPL): S179-S180. doi:10.14309/01. ajg.0000774092.07631.9d.









Erin Ferries, PhD, MPH¹*, Susan Suponcic, BA, MA, MSc, PhD², Sophia Chung, BA³, Sayak Bhattacharya, BA³, Aishwarya Kulkarni, MS³, Mason Yeh, PhD³, Abigail Silber, MPH³, Matt O'Hara, MBA³, Phong Duong, PharmD⁴ 1. Mindmed, HEOR, Denver, CO; 2. Value and Access Advisors, LLC, St. Petersburg, FL; 3. Trinity Life Sciences, Waltham, MA; 4. Mindmed, New York, NY

REFERENCES

56.Kaye A, Patel S, Meyers S, Shah V, Mathew A, Ahlawat S. Outcomes of Patients Hospitalized for Inflammatory Bowel Disease With Comorbid Generalized Anxiety Disorder. Am. J. Gastroenterol. 2022;117(10):S737. doi:10.14309/01.ajg.0000860708.34581.8a. 57.Saleh S, Desai A, Trujillo S, Waghray N. Risk of generalized anxiety disorder and its impact on patients with inflammatory bowel disease: A nationwide population-based cohort study. Am. J. Gastroenterol. 2021;116(SUPPL):S452. doi:10.14309/01.ajg.0000777320.35746.c1. 58. Jin-Dominguez F, Mansoor E, Wong R, Cooper G. EPIDEMIOLOGY OF PSYCHIATRIC DISORDERS IN IRRITABLE BOWEL SYNDROME IN THE UNITED STATES BETWEEN 2014 AND 2019: A POPULATION-BASED NATIONAL STUDY. Gastroenterology. 2020;158(6):S-851-S-852. doi:10.1016/s0016-5085(20)32806-7. 59.Zeynalova N, Schimpf S, Setter C, et al. The association between an anxiety disorder and cancer in medical history. J Affect Disord. 2019;246:640-642. doi:10.1016/j.jad.2018.12.019. 60.Huynh SArch J, Genung S, Ferris M, et al. Presence and predictors of anxiety disorder onset following cancer survivors. Support Care Cancer. 2020;28(9):4425-4433. doi:10.1007/s00520-020-05297-0. 61. Lee L, Jaffe D, Haskell T. PNS374 CLINICAL BURDEN AND HEALTH RECORDS TO PATIENT-REPORTED OUTCOMES. Value Health. 2019;22:S828. doi:10.1016/j.jval.2019.09.2274. 62. Lin S, Tyus N, Maloney M, Ohri B, Sripipatana A. Mental health. A cross-sectional study. PLoS One. 2020;15(4):e0231243. doi:10.1371/journal.pone.0231243. 63. Osborne L, Voegtline K, Standeven L, et al. High worry in pregnancy predicts postpartum depression. J Affect Disord. 2021;294:701-706. doi:10.1016/j.jad.2021.07.009. 64. Kim H, Erickson N, Flynn J. Keeping Parent, Child, and Relationship in Mind: Clinical Effectiveness of a Trauma-informed, Multigenerational, Attachment-Based, Mother-Based, Mother-Ba 65. Miller M, O'Hara M. The structure of mood and anxiety disorder symptoms in the perinatal period. J. Affective Disord. 2023;325:231-239. doi:10.1016/j.jad.2022.12.111. 66. Chen K, Hynes K, Dirschl D, Wolf J, Strelzow J. Depression, anxiety, and post-traumatic stress disorder following upper versus lower extremity fractures. Injury. 2024;55(3). doi:10.1016/j.injury.2023.111242. 67. Shirshendu S, Unlu H, Kadari M, et al. Cannabis and liver transplant: Navigating through the outcome dynamics. J. Psychosom. Res. 2024;181. doi:10.1016/j.jpsychores.2024.111773. 68. Hudock N, Kshir S, Taylor K. Post-traumatic Stress Disorder as an Independent Risk Factor for Increased Opioid Use Following Carpal Tunnel Surgery. Hand (N Y). 2024;19(6):1012-1018. doi:10.1177/15589447231160207. 69. Armbrecht E, Shah R, Poorman G, et al. Economic and humanistic burden associated with depression and anxiety among adults with non-communicable chronic diseases (Nccds) in the united states. J. Multidiscip. Healthc. 2021;14:887-896. doi:10.2147/jmdh.s280200. 70. Viola M, Lohitsa A. 180 Is Mental Health Treatment Associated With Decreased Emergency Department Utilization?. Ann. Emerg. Med. 2019;74(4):S71. doi:10.1016/j.annemergmed.2019.08.186. 71. Kelly K, Ratliff S, Mezuk B. Allergies, asthma, and psychopathology in a nationally-representative US sample. J Affect Disord. 2019;251:130-135. doi:10.1016/j.jad.2019.03.026. 72. Helm M, Bazewicz C, Butt M, Shumaker K, Foulke G. 1027 Psychosocial toll of dermatomyositis: Does malignancy risk play a role?. J. Invest. Dermatol. 2019;139(5):S177. doi:10.1016/j.jid.2019.03.1103. 73. Beer L, Tie Y, Padilla M, Shouse R, Generalized anxiety disorder symptoms among persons with diagnosed HIV in the United States. AIDS. 2019;33(11):1781-1787. doi:10.1097/qad.000000000002286. 74. Li K, Smedberg D, DeLisi L. A Retrospective 4-year Outcome Study of Veterans Admitted to an Acute Inpatient Detoxification Unit for Opioid Use Disorder. Am J Addict. 2019;28(4):318-323. doi:10.1111/ajad.12893. 75. Tejesh V, Anupama M. Psychiatric co morbidities in HIV patients. Indian J. Psychiatry. 2023;65:S75-S76. 76. Brown M, Cohen S, DeShazo J. Psychopathology and HIV diagnosis among older adults in the United States: disparities by age, sex, and race/ethnicity. Aging Ment Health. 2020;24(10):1746-1753. doi:10.1080/13607863.2019.1636201. 77. Ghoneim S, Dalal S, Shah A, et al. The epidemiology of celiac disease among adult patients: A population-based study. Am. J. Gastroenterol. 2020;115(SUPPL):S644-S645. 78. Weiss S, Elyze M, Starzyk K. RWD62 Real-World Characterization and Management of Alopecia Areata Patients in the U.S. Value Health. 2023;26(6):S372. doi:10.1016/j.jval.2023.03.2091. 79. Grant J, Chamberlain S. Prevalence of skin picking (excoriation) disorder. J Psychiatr Res. 2020;130:57-60. doi:10.1016/j.jpsychires.2020.06.033. 80. Mostaghimi L. Psychocutaneous Medicine Clinic: Wisconsin Experience. J Acad Consult Liaison Psychiatry. 2021;62(5):522-527. doi:10.1016/j.jaclp.2021.04.008. 81. Grant J, Chamberlain S. Characteristics of 262 adults with skin picking disorder. Compr. Psychiatry. 2022;117. doi:10.1016/j.comppsych.2022.152338. 82. Weiss S, Elyze M, Starzyk K. RWD28 Patient Characteristics and Social Determinants of Health in a Large Real-World Cohort of Vitiligo Patients in the U.S. Value Health. 2023;26(6):S365. doi:10.1016/j.jval.2023.03.2058. 83. Shepherd-Banigan M, Miller K, Hastings S, Schleiden L, Thorpe J. Use of high cost care among Veterans with comorbid mental illness and Alzheimer's Disease and related dementias. PLoS One. 2023;18(5):e0282071. doi:10.1371/journal.pone.0282071. 84. Riley J, Gleghorn D, Doudican B, Cha Y. Psychological assessment of individuals with Mal de Débarquement Syndrome. J Neurol. 2022;269(4):2149-2161. doi:10.1007/s00415-021-10767-4. 85. Buse D, Yugrakh M, Lee L, Bell J, Cohen J, Lipton R. Burden of Illness Among People with Migraine. J Manag Care Spec Pharm. 2020;26(10):1334-1343. doi:10.18553/jmcp.2020.20100. 86. Shoair O, Cook E, Shipman D, Dunn R. Antidepressant Target Dose Optimization and Control of Severe Asthma Exacerbations in Uninsured Patients with Anxiety and/or Depression. Pharmacotherapy. 2020;40(4):320-330. doi:10.1002/phar.2374. 87. Kalra S, Jaber J, Alzghoul B, et al. Pre-Existing Psychiatric Illness Is Associated With an Increased Risk of Delirium in Patients With Acute Respiratory Distress Syndrome. J. Intensive Care Med. 2022;37(5):647-654. doi:10.1177/08850666211019009. 88. Jaber J, Reddy R, Hyde R, et al. PREEXISTING PSYCHIATRIC ILLNESS IS ASSOCIATED WITH HIGHER INCIDENCE OF DELIRIUM IN ARDS. Chest. 2020;158(4):A578. doi:10.1016/j.chest.2020.08.546. 89. Dhingra R, He F, Saunders E, et al. Cardiovascular disease burden in a psychiatric outpatient population. Circulation. 2021;143(SUPPL 1). doi:10.1161/circ.143.suppl 1.060. 90. Matloub S, Thordsen S. MENTAL HEALTH OUTCOMES IN A LOCAL PERIPARTUM CARDIOMYOPATHY COHORT. J. Am. Coll. Cardiol. 2024;83(13):2425. doi:10.1016/s0735-1097(24)04415-2. 91. Cooke D, Shen H, Duvvuri M, et al. Association of select psychiatric disorders with incident brain aneurysm and subarachnoid hemorrhage among veterans. Front. Integr. Neurosci. 2023;17. doi:10.3389/fnint.2023.1207610. 92. Leonard K, Abramovitch A. Cognitive functions in young adults with generalized anxiety disorder. Eur Psychiatry. 2019;56:1-7. doi:10.1016/j.eurpsy.2018.10.008. 93. Prince E, Siegel D, Carroll C, Sher K, Bienvenu O. A longitudinal study of personality traits, anxiety, and depressive disorders in young adults. Anxiety Stress Coping. 2021;34(3):299-307. doi:10.1080/10615806.2020.1845431. 94. Kiekens G, Hasking P, Bruffaerts R, et al. Non-suicidal self-injury among first-year college Student (WMH-ICS) initiative. Psychol Med. 2023;53(3):875-886. doi:10.1017/s0033291721002245. 95. Washington J, Milligan N, Brownlow J. AN INVESTIGATION OF SLEEP DISTURBANCE, DEPRESSION, AND ANXIETY AMONG EMERGING ADULTS. Sleep. 2024;47:A413. doi:10.1093/sleep/zsae067.0963. 96. Kalmbach D, Abelson J, Arnedt J, Zhao Z, Schubert J, Sen S. Insomnia symptoms and short study of medical interns. Sleep Med. 2019;55:40-47. doi:10.1016/j.sleep.2018.12.001. 97. Fitzpatrick S, Maich K, Carney C, Kuo J. Identifying specific insomnia components in borderline personality disorder and their influence on emotion dysregulation. Personal Disord. 2020;11(6):440-450. doi:10.1037/per0000395. 98. Kaczkurkin A, Tyler J, Turk-Karan E, Belli G, Asnaani A. The Association between Insomnia and Anxiety Treatment Setting. Behav Sleep Med. 2021;19(1):110-125. doi:10.1080/15402002.2020.1714624. 99. Mendelsohn A, Daffre C, Oliver K, Seo J, Lasko N, Pace-Schott E. Anxiety and sleep in generalized anxiety disorder. Sleep. 2021;44(SUPPL 2):A298. doi:10.1093/sleep/zsab072.762. 100.Daffre C, Oliver K, Valli B, Kleckner I, Pace-Schott E. Interactions among interoceptive sensitivity and insomnia symptoms in individuals with generalized anxiety disorder. Sleep. 2020;43(SUPPL 1):A424-A425. doi:10.1093/sleep/zsaa056.1111. 101.Donovan L, Malte C, Spece L, et al. Long-term benzodiazepine use among patients with chronic obstructive pulmonary disease and comorbid posttraumatic stress disorder. Am. J. Respir. Crit. Care Med. 2019;199(9). 102.Tolin D, Lee E, Levy H, et al. Psychophysiological assessment of stress reactivity and recovery in anxiety disorders. J Anxiety Disord. 2021;82:102426. doi:10.1016/j.janxdis.2021.102426. 103. Duong P, Suponcic S, Finlayson K, Li V, Karlin D. PCR38 Health-Related Quality of Life Associated with Generalized Anxiety Disorder Among Adults in the United States. Value Health. 2024;27(6):S302-S303. doi:10.1016/j.jval.2024.03.1645. 104. Mannes Z, Hearn L, Zhou Z, Janelle J, Cook R, Ennis N. The association between symptoms of generalized anxiety disorder and appointment adherence, overnight hospitalization, and emergency department/urgent care visits among adults living with HIV enrolled in care. J Behav Med. 2019; 42(2): 330-341. doi:10.1007/s10865-018-9988-6.









Erin Ferries, PhD, MPH¹*, Susan Suponcic, BA, MA, MSc, PhD², Sophia Chung, BA³, Sayak Bhattacharya, BA³, Aishwarya Kulkarni, MS³, Mason Yeh, PhD³, Abigail Silber, MPH³, Matt O'Hara, MBA³, Phong Duong, PharmD⁴ 1. Mindmed, HEOR, Denver, CO; 2. Value and Access Advisors, LLC, St. Petersburg, FL; 3. Trinity Life Sciences, Waltham, MA; 4. Mindmed, New York, NY

ABBREVIATIONS

ADL: Activities of Daily Living AI: Artificial Intelligence **BPD: Borderline Personality Disorder** C. Difficile: Clostridium Difficile DALY: Disability-Adjusted Life Year DSM-5: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition GAD: Generalized Anxiety Disorder GERD: Gastroesophageal Reflux Disease HCRU: Healthcare Resource Utilization HIV: Human Immunodeficiency Virus HRQoL: Health-related Quality of Life IBD: Inflammatory Bowel Disease **IBS: Irritable Bowel Syndrome** ICU: Intensive Care Unit MDD: Major Depressive Disorder OCD: Obsessive Compulsive Disorder PICOS: Population, Intervention, Comparator, Outcomes, and Study Design PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses PTSD: Post-Traumatic Stress Disorder QALY: Quality-Adjusted Life Year QoL: Quality of Life **RCT: Randomized Controlled Trial** SAD: Social Anxiety Disorder SLR: Systematic Literature Review US: United States





